Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.83 HKD | +4.08% | +6.09% | -45.67% |
Mar. 07 | OrbusNeich Medical Group’s Profit Up 144% in 2023 | MT |
Mar. 07 | OrbusNeich Medical Group Holdings Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 28 June 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.98 for the 2024 fiscal year.
- The company has a low valuation given the cash flows generated by its activity.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-45.67% | 405M | - | ||
+12.07% | 128B | A- | ||
-9.04% | 10.65B | A- | ||
+0.91% | 8.82B | C | ||
+16.72% | 7.19B | C | ||
+25.15% | 4.99B | B+ | ||
+7.17% | 3.4B | C- | ||
-1.36% | 3.03B | B- | ||
-8.73% | 2.14B | - | - | |
-10.15% | 2B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6929 Stock
- Ratings OrbusNeich Medical Group Holdings Limited